Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 2.7 %

NASDAQ EGRX opened at $3.95 on Thursday. Eagle Pharmaceuticals has a 12-month low of $3.21 and a 12-month high of $15.91. The firm’s fifty day simple moving average is $4.50 and its two-hundred day simple moving average is $4.65. The firm has a market capitalization of $51.30 million, a P/E ratio of 3.35 and a beta of 0.53.

Institutional Trading of Eagle Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 2.1% in the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after buying an additional 25,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 2,630 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock worth $1,005,000 after purchasing an additional 100,470 shares during the period. Perceptive Advisors LLC purchased a new position in Eagle Pharmaceuticals during the second quarter worth about $971,000. Finally, Trexquant Investment LP increased its holdings in Eagle Pharmaceuticals by 88.0% in the 4th quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock valued at $660,000 after purchasing an additional 59,095 shares during the last quarter. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.